Post by icemandios on Dec 23, 2020 13:52:46 GMT
ViewRay to Present at the 39th Annual J.P. Morgan Healthcare Conference
PR Newswire
CLEVELAND , Dec. 23, 2020 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced its participation in the 39th Annual J.P. Morgan Healthcare Conference. Scott Drake , President and CEO, is scheduled to present at 10:50 a.m. Eastern Time on Thursday , January 14, 2021.
An audio webcast of the Company's presentation will be available on the "Financial Events and Webinars" portion of ViewRay's investor website at investors.viewray.com/events-and-presentations/upcoming-events . A replay of the webcast will be available for 14 days after the date of the presentation.
About ViewRay
ViewRay, Inc. (Nasdaq: VRAY), designs, manufactures, and markets the MRIdian® radiation therapy system. MRIdian is built upon a proprietary high-definition MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation oncology. Unlike MR systems used in diagnostic radiology, MRIdian's high-definition MR was purpose built to address specific challenges, including beam distortion, skin toxicity, and other concerns that potentially may arise when high magnetic fields interact with radiation beams. ViewRay and MRIdian are registered trademarks of ViewRay, Inc.
PR Newswire
CLEVELAND , Dec. 23, 2020 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced its participation in the 39th Annual J.P. Morgan Healthcare Conference. Scott Drake , President and CEO, is scheduled to present at 10:50 a.m. Eastern Time on Thursday , January 14, 2021.
An audio webcast of the Company's presentation will be available on the "Financial Events and Webinars" portion of ViewRay's investor website at investors.viewray.com/events-and-presentations/upcoming-events . A replay of the webcast will be available for 14 days after the date of the presentation.
About ViewRay
ViewRay, Inc. (Nasdaq: VRAY), designs, manufactures, and markets the MRIdian® radiation therapy system. MRIdian is built upon a proprietary high-definition MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation oncology. Unlike MR systems used in diagnostic radiology, MRIdian's high-definition MR was purpose built to address specific challenges, including beam distortion, skin toxicity, and other concerns that potentially may arise when high magnetic fields interact with radiation beams. ViewRay and MRIdian are registered trademarks of ViewRay, Inc.